Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cance... (s appropriate to complement its internal...)

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients

Date:4/14/2008

s appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007, include information about additional factors that could affect the Company's financial and operating results.

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Medivation Announces Senior Management Promotions
2. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
3. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Boston Scientific Announces Japanese Approval of Heart Failure Lead
6. Vasogen Announces Implementation of Strategic Restructuring Plan
7. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
8. EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
9. Botaneco Announces Launch of Second Generation Oleosome Product
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Signalife Announces Webcast

Post Your Comments:

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cance...(s appropriate to complement its internal...)